Comprehensive medication guide to Ebglyss including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50 copay with commercial insurance; prior authorization and step therapy typically required, dispensed through specialty pharmacy.
Estimated Cash Pricing
$2,500–$3,800 per injection ($3,200/month maintenance); Eli Lilly Savings Card may reduce cost to $0 for eligible commercially insured patients.
Medfinder Findability Score
35/100
Summarize with AI
On this page
Ebglyss (Lebrikizumab-lbkz) is a biologic medication made by Eli Lilly for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 and older who weigh at least 40 kg (88 lb). It is approved for patients who are candidates for systemic therapy — meaning topical treatments alone haven't been enough to control their symptoms. Ebglyss is administered as a subcutaneous injection that patients can self-administer at home after proper training.
Ebglyss is a humanized monoclonal antibody that specifically targets and blocks , a key cytokine that drives type 2 inflammation. IL-13 plays a central role in the skin barrier dysfunction, inflammation, itching, and thickening seen in atopic dermatitis. By binding to IL-13 and preventing it from signaling, Ebglyss reduces the inflammatory cascade responsible for eczema flares, helping to clear skin and relieve itch.
![How to Find a Doctor Who Can Prescribe Ebglyss Near You [2026 Guide]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F68cd4cb6d0f4e57b33bbaf465ab2a7bf38cc8c4d-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
![Why Is Ebglyss So Hard to Find? [Explained for 2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F62f33b635c01832f8e80331b9316f0495c3cb76a-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
250 mg/2 mL prefilled syringe
250 mg/2 mL prefilled pen
Ebglyss (Lebrikizumab-lbkz) has a findability score of 35 out of 100, meaning it can be quite difficult to locate. As a newly launched specialty biologic approved by the FDA in September 2024, Ebglyss is not stocked at most retail pharmacies. It is almost exclusively dispensed through specialty pharmacies, which require prior authorization from your insurance. Supply is still ramping up following early manufacturing delays that initially postponed FDA approval in 2023. If your dermatologist prescribes Ebglyss, expect the specialty pharmacy coordination process to take several days to a few weeks.
Ebglyss is typically prescribed by dermatologists and allergists/immunologists who specialize in managing moderate-to-severe atopic dermatitis. Pediatric dermatologists may also prescribe it for adolescents aged 12 and older. Because most insurance plans require prior authorization and evidence that other treatments have been tried first, your prescribing doctor will usually need to submit documentation of your treatment history. Telehealth consultations are available for some follow-up visits.
No. Ebglyss is not a controlled substance and has no DEA scheduling. It is a biologic medication that does not carry abuse or dependence potential. However, it does require a prescription and is dispensed through specialty pharmacies.
Eye-related side effects are notably common with Ebglyss. Contact your doctor if you experience persistent eye pain, redness, or vision changes. Serious but rare side effects include hypersensitivity reactions, herpes zoster (shingles), and parasitic infections.
Know what you need? Skip the search.
Dupixent (Dupilumab)
An IL-4/IL-13 dual inhibitor biologic injection, the most widely used biologic for moderate-to-severe atopic dermatitis
Adbry (Tralokinumab)
Another IL-13 inhibitor monoclonal antibody for moderate-to-severe atopic dermatitis
Rinvoq (Upadacitinib)
A JAK inhibitor oral tablet for moderate-to-severe atopic dermatitis
Cibinqo (Abrocitinib)
A JAK inhibitor oral tablet for moderate-to-severe atopic dermatitis
Prefer Ebglyss? We can find it.
Live vaccines
moderateShould not be administered during Ebglyss treatment. Make sure all vaccinations are up to date before starting.
Other immunosuppressants
moderateTheoretical risk of additive immunosuppression when combined with other immunosuppressive therapies
Narrow therapeutic index CYP450 substrates
moderateIL-13 inhibition may restore CYP450 enzyme activity previously suppressed by chronic inflammation, potentially affecting levels of drugs like Warfarin or Theophylline
Ebglyss is an important new option for people living with moderate-to-severe atopic dermatitis, especially those who haven't responded well to other treatments. As a targeted IL-13 inhibitor, it offers a focused approach to reducing inflammation and itch. The main challenges right now are availability and cost — it's a specialty-pharmacy-only biologic with a high cash price, though Eli Lilly's savings programs can significantly reduce out-of-pocket costs. If you're having trouble finding Ebglyss, Medfinder can help you locate specialty pharmacies that carry it.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini